Broadcast Date: November 3, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
The pharmaceutical industry relies heavily on the use of in-vitro mammalian cell culture systems for drug discovery. Through in-vitro cell studies, targeted effects such as efficacy and toxicity can be tested before expensive animal studies, to select compounds with a higher probability of success. However, it has been estimated that about 50% of drug failures in the preclinical phase are due to issues that could have been identified during drug discovery/toxicology testing—citing the need for more robust and reliable cellular tools and methods. The recent development of CRISPR technology for genome modification offers new possibilities for labeling endogenous targets with molecular tags to study proteins under physiological conditions without cell fixing, chemical staining, or antibodies.
In this GEN webinar, we will discuss the development of the FAST-HDR vector system select patent pending)—a novel set of plasmids to be used in combination with CRISPR for the rapid development of multi-tagged cell lines for drug discovery. These plasmids allow the insertion of protein tags in genes of interest for downstream applications such as high-content imaging or luminescence detection on live cells. We will present examples of the use of these enhanced cellular models for high-throughput screening, target characterization, and live-cell microscopy.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Oscar Perez-Leal, MD
Eugene Gibbs II, PhD